AT2 receptor agonists: hypertension and beyond
Current opinion in nephrology and hypertension, 2012•journals.lww.com
Availability of nonpeptidic, orally active AT2R agonists will facilitate future AT2R research
and hopefully contribute to the clarification of many still open questions regarding AT2R
signalling and function. Furthermore, AT2R agonists represent a potential novel class of
drugs and are expected to enter a phase I clinical study in 2012.
and hopefully contribute to the clarification of many still open questions regarding AT2R
signalling and function. Furthermore, AT2R agonists represent a potential novel class of
drugs and are expected to enter a phase I clinical study in 2012.
Summary
Availability of nonpeptidic, orally active AT2R agonists will facilitate future AT2R research and hopefully contribute to the clarification of many still open questions regarding AT2R signalling and function. Furthermore, AT2R agonists represent a potential novel class of drugs and are expected to enter a phase I clinical study in 2012.
Lippincott Williams & Wilkins